{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:37:44Z","timestamp":1761100664168,"version":"3.30.2"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2004,1,19]],"date-time":"2004-01-19T00:00:00Z","timestamp":1074470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2004,1,19]],"date-time":"2004-01-19T00:00:00Z","timestamp":1074470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2004,3,1]]},"DOI":"10.1038\/sj.bmt.1704379","type":"journal-article","created":{"date-parts":[[2004,1,19]],"date-time":"2004-01-19T10:17:33Z","timestamp":1074507453000},"page":"477-482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results from the Spanish multicenter prospective trial"],"prefix":"10.1038","volume":"33","author":[{"given":"M","family":"G\u00f3mez-N\u00fa\u00f1ez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Martino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M D","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J A","family":"P\u00e9rez-Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Canals","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M V","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Sarr\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Solano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J M","family":"Moraleda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Urbano-Ispizua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Besalduch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J S","family":"Miguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,1,19]]},"reference":[{"key":"BF1704379_CR1","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V89.12.4531","volume":"89","author":"S Giralt","year":"1997","unstructured":"Giralt S, Estey E, Albitar M . Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531\u20134536.","journal-title":"Blood"},{"key":"BF1704379_CR2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1182\/blood.V97.3.631","volume":"97","author":"S Giralt","year":"2001","unstructured":"Giralt S, Thall PF, Khouri I et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631\u2013637.","journal-title":"Blood"},{"key":"BF1704379_CR3","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","volume":"91","author":"S Slavin","year":"1998","unstructured":"Slavin S, Nagler A, Naparstek T et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with letal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756\u2013763.","journal-title":"Blood"},{"key":"BF1704379_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/sj.bmt.1702204","volume":"25","author":"AM Carella","year":"2000","unstructured":"Carella AM, Champlin R, Slavin S et al. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant 2000; 25: 345\u2013350.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704379_CR5","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","volume":"97","author":"PA McSweeney","year":"2001","unstructured":"McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with marrow transplantation: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390\u20133400.","journal-title":"Blood"},{"key":"BF1704379_CR6","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1182\/blood.V96.7.2419","volume":"96","author":"PD Kottaridis","year":"2000","unstructured":"Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419\u20132425.","journal-title":"Blood"},{"key":"BF1704379_CR7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1046\/j.1365-2141.2001.03153.x","volume":"115","author":"R Martino","year":"2001","unstructured":"Martino R, Caballero MD, Canals C et al Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol 2001; 115: 653\u2013659.","journal-title":"Br J Haematol"},{"key":"BF1704379_CR8","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P et al. 1994 Consense conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825\u2013828.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704379_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.bmt.1703846","volume":"31","author":"D Valcarcel","year":"2003","unstructured":"Valcarcel D, Martino R, Caballero D et al. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2003; 31: 387\u2013392.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704379_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/sj.bmt.1703382","volume":"29","author":"LL Popplewell","year":"2002","unstructured":"Popplewell LL, Forman SJ . Is there an upper age limit for bone marrow transplantation? Bone Marrow Transplant 2002; 29: 277\u2013284.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704379_CR11","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1200\/JCO.1986.4.10.1489","volume":"4","author":"KG Blume","year":"1986","unstructured":"Blume KG, Forman SJ, Nademanee A . Bone marrow transplantation for hematologic malignancies in patients aged 30 years or older. J Clin Oncol 1986; 4: 1489\u20131492.","journal-title":"J Clin Oncol"},{"key":"BF1704379_CR12","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1182\/blood.V67.3.770.770","volume":"67","author":"H-G Klingemann","year":"1986","unstructured":"Klingemann H-G, Storb R, Fefer A et al. Bone marrow transplantation in patients aged 45 years and older. Blood 1986; 67: 770\u2013776.","journal-title":"Blood"},{"key":"BF1704379_CR13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1399-0012.1994.tb00250.x","volume":"8","author":"J Aschan","year":"1994","unstructured":"Aschan J, Ringden O . Prognostic factors for long-term survival in leukemia marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease. Clin Transplant 1994; 8: 258\u2013270.","journal-title":"Clin Transplant"},{"key":"BF1704379_CR14","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1182\/blood.V95.4.1188.004k38_1188_1194","volume":"95","author":"HJ Deeg","year":"2000","unstructured":"Deeg HJ, Shulman H, Anderson JE et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 2000; 95: 1188\u20131194.","journal-title":"Blood"},{"key":"BF1704379_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/sj.bmt.1703606","volume":"30","author":"R Martino","year":"2002","unstructured":"Martino R, Caballero MD, de la Serna J et al. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced intensity- conditioning in adult patients who had failed a prior autologous transplant. Bone Marrow Transplant 2002; 30: 63\u201368.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704379_CR16","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1200\/JCO.2002.11.088","volume":"20","author":"K Branson","year":"2002","unstructured":"Branson K, Chopra R, Kottaridis PD et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002; 20: 4022\u20134031.","journal-title":"J Clin Oncol"},{"key":"BF1704379_CR17","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1182\/blood-2002-03-0701","volume":"100","author":"JA Perez-Sim\u00f3n","year":"2002","unstructured":"Perez-Sim\u00f3n JA, Kottaridis PD, Martino R et al. Nonmyeolablative transplantation with or without alemtuzumab: comparison with 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002; 100: 3121\u20133127.","journal-title":"Blood"},{"key":"BF1704379_CR18","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1182\/blood-2002-02-0400","volume":"100","author":"R Martino","year":"2002","unstructured":"Martino R, Caballero MD, Perez-Simon JA et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 2002; 100: 2243\u20132245.","journal-title":"Blood"},{"key":"BF1704379_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1046\/j.1365-2141.2003.04237.x","volume":"121","author":"JA Perez-Simon","year":"2003","unstructured":"Perez-Simon JA, Martino R, Alegre A et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol 2003; 121: 104\u2013108.","journal-title":"Br J Haematol"},{"key":"BF1704379_CR20","doi-asserted-by":"crossref","unstructured":"Perez-Simon JA, Diez-Campelo M, Martino R et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced intensity conditioning allogeneic peripheral blood stem cell transplantation. Blood 2003, (in press).","DOI":"10.1182\/blood-2002-11-3503"},{"key":"BF1704379_CR21","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1182\/blood-2002-12-3629","volume":"102","author":"M Mohty","year":"2003","unstructured":"Mohty M, Bay JO, Faucher C et al. Graft-versus-host disease following allogeneic HLA-identical sibling transplantation with anti-thymocyte globulin based reduced intensity preparative regimen. Blood 2003; 102: 470\u2013476.","journal-title":"Blood"},{"key":"BF1704379_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/sj.bmt.1703150","volume":"28","author":"R Martino","year":"2001","unstructured":"Martino R, Caballero MD, Canals C et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 28: 341\u2013347.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704379_CR23","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1182\/blood-2003-02-0456","volume":"102","author":"T Fukuda","year":"2003","unstructured":"Fukuda T, Boeckh M, Carter RA et al. Invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplantation after nonmyeloablative conditioning: risks and outcomes. Blood 2003; 102: 827\u2013833.","journal-title":"Blood"},{"key":"BF1704379_CR24","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1053\/bbmt.2002.v8.pm12374456","volume":"8","author":"C Junghanss","year":"2002","unstructured":"Junghanss C, Marr KA, Carter RA et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002; 8: 512\u2013520.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1704379_CR25","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1182\/blood.V99.3.1071","volume":"99","author":"R Chakraverty","year":"2002","unstructured":"Chakraverty R, Peggs K, Chopra R et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071\u20131078.","journal-title":"Blood"},{"key":"BF1704379_CR26","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1182\/blood-2002-05-1340","volume":"101","author":"D Niederwieser","year":"2003","unstructured":"Niederwieser D, Maris M, Shizuru JA et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA matched or mismatched unrelated donors postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620\u20131629.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1704379","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1704379.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1704379.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T23:35:20Z","timestamp":1734219320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1704379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,19]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,3,1]]}},"alternative-id":["BF1704379"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1704379","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2004,1,19]]},"assertion":[{"value":"29 May 2003","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2003","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2004","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}